Can Bristol-Myers Squibb Company (BMY) Provide Stable Long-Term Income?

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 10 Best Passive Income Stocks to Buy Now.

On June 17, the company declared a quarterly dividend of $0.62 per share, which was consistent with its previous dividend. Overall, it has raised its payouts for 16 consecutive years and has delivered uninterrupted payouts for 93 years in a row. The stock offers a dividend yield of 5.2%, as of July 10.

Bristol-Myers Squibb Company (NYSE:BMY)’s cash position remained strong in the first quarter of 2025. The company ended the quarter with $10.8 billion available in cash and cash equivalents, up from $10.3 billion at the end of December 2024. Its Q1 revenue of $11.2 billion, though down by 5.6% on a YoY basis, beat analyst estimates by $494.6 million.

Bristol-Myers Squibb Company (NYSE:BMY) is an American multinational pharmaceutical company that specializes in developing and delivering innovative medicines. The stock has surged by 16% in the past 12 months.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Dividend Aristocrat Stocks to Invest in Now and 10 Best Stocks to Buy For Dividends

Disclosure: None.